Takeda Pharmaceutical Company

CalciMedica Expands Executive Team with New Appointments

Retrieved on: 
Tuesday, May 23, 2023
Takeda Pharmaceutical Company, Leadiant Biosciences, Hospice and palliative medicine, Medicine, Diffusion Pharmaceuticals, Head, New Drug Application, Drug, Associate, Acute kidney injury, Patient, Acute pancreatitis, Knowledge, Regulatory affairs, FDA, Reata Pharmaceuticals, Inflammation, Pharmaceutical industry

Both Mrs. Jaeger and Dr. Cunningham bring extensive expertise to their positions on the CalciMedica team.

Key Points: 
  • Both Mrs. Jaeger and Dr. Cunningham bring extensive expertise to their positions on the CalciMedica team.
  • While at BridgeBio Pharma, she led her team to the first FDA approved New Drug Application across all subsidiaries of the organization.
  • “I am excited to join the CalciMedica team and to build on the clinical progress of Auxora in multiple indications by spearheading regulatory strategy,” said Mrs. Jaeger.
  • We are delighted to welcome Raven and Andrew to the CalciMedica team,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.

Harvard Professor and Entrepreneur Tim Springer Donates $210 Million to the Institute for Protein Innovation

Retrieved on: 
Wednesday, May 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Other Health, Takeda Pharmaceutical Company, Informatics, Nobel Prize, Vedolizumab, University, Human genome, Therapy, Doctor of Philosophy, Berkeley, Boston Children's Hospital, Biomedical Research, Disease, Genomics, Genome, Cell, Antibody, Harvard Medical School, Protein, Albert Lasker Award for Basic Medical Research, Patient, Human, Takeda Oncology, Integrin, IPI, Springer, ARD International Music Competition, Biology, Growth, Hospital, Human Genome Project, Gene, Pharmaceutical industry, Fine chemical, Vaccine

The Institute for Protein Innovation (IPI) , a nonprofit research organization, announced today a $210 million gift from Tim Springer, Ph.D., veteran entrepreneur and professor at Harvard Medical School and Boston Children’s Hospital, who founded IPI in 2017 with Andrew Kruse, Ph.D.

Key Points: 
  • The Institute for Protein Innovation (IPI) , a nonprofit research organization, announced today a $210 million gift from Tim Springer, Ph.D., veteran entrepreneur and professor at Harvard Medical School and Boston Children’s Hospital, who founded IPI in 2017 with Andrew Kruse, Ph.D.
  • The philanthropic gift—made by Springer, his wife Chafen Lu, Ph.D., and their children—adds to previous gifts of $40 million to IPI from Springer himself.
  • “Thanks to Tim’s commitment, IPI will be able to take on more challenging problems in protein science that academia and industry cannot or will not.
  • Springer has previously endowed professorships and chairs at Harvard Medical School, Boston Children's Hospital and the University of California, Berkeley.

Government of Japan Expresses its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment

Retrieved on: 
Thursday, May 25, 2023
Vaccine, Takeda Pharmaceutical Company, Partnership, Government of Japan, Neglected tropical diseases, Therapy, Shionogi, United Nations, Daiichi Sankyo, Risk management, Merck Group, UNDP, Research, Infection, Global Health Innovative Technology Fund, Bill & Melinda Gates Foundation, Government, Fujifilm, PPP, Climate change, Investment, Tuberculosis, Patient, United Nations Development Programme, Bill, R, Environment, Tropical disease, Malaria, Pharmaceutical industry, Limited, Wellcome

TOKYO, May 25, 2023 /PRNewswire/ -- At the G7 Hiroshima Summit 2023, Prime Minister Fumio Kishida announced the Government of Japan's pledge to contribute US$200 million to the Global Health Innovative Technology Fund (GHIT Fund)/United Nations Development Programme (UNDP). This pledge supports the GHIT Fund's third phase of operations, including investments in research and development (R&D) of drugs, vaccines and diagnostics, utilizing Japan's innovation and expertise to prevent and address infectious diseases such as tuberculosis, malaria and neglected tropical diseases (NTDs), which are highly prevalent in low- and middle-income countries.

Key Points: 
  • In addition to the new contribution from the Government of Japan, support from industry for GHIT's replenishment has increased compared to previous replenishments.
  • Additionally, founding foundation partners Bill & Melinda Gates Foundation and Wellcome will continue to support GHIT.
  • Over the next five years, the GHIT Fund will strive to secure additional support with a total replenishment goal of US$400 million to support operations and investments.
  • This replenishment supports the implementation of "GHIT 3.0," the institution's third five-year plan, as follows.

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

Retrieved on: 
Monday, May 22, 2023
University, Data management, BS, Senior, Statistics, Simon de Montfort, 6th Earl of Leicester, TPD, Research, Doctor of Philosophy, Sequah Medicine Company, Shire (pharmaceutical company), Patient, Vertex Pharmaceuticals, United Kingdom, Biostatistics, Therapy, Takeda Pharmaceutical Company, Fine chemical, Medical device, Mathematics, Takeda

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

Key Points: 
  • WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.
  • Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies.
  • As a member of the Company’s senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera’s expanding pipeline.
  • He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the United Kingdom.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Global $70 Billion Regenerative Medicine Market Analysis to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023
Health, Pharmaceutical, GSK, Amgen, The Global Institute for Tomorrow, COVID-19, Bayer, Medicine, Infection, Food, Takeda Pharmaceutical Company, Cancer, Foreign Affairs, Paratriathlon, Multinational corporation, DSM-IV codes, Prostate, United States Department of Health and Human Services, AstraZeneca, Lung, Stomach, Colon, Regenerative medicine, Ministry, Death, GSK plc, Criticism of the Food and Drug Administration, Rectum, Patent, Patient, Immune system, Voretigene neparvovec, Conditional sentence, Growth, Integra LifeSciences, Region, FDA, Vericel, B cell, Ministry of Economics (Latvia), United Arab Emirates, Skin, World Health Organization, Novartis, Pharmaceutical industry, Vaccine, Video game, Economics, Research

The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.
  • The Global Regenerative Medicine Market - which grew from approximately US$ 15 billion in 2017 to approximately US$ 30 billion in 2022 - is forecasted to grow further into approximately US$ 70 billion opportunities by 2028, owing to the growing severe diseases, infections, and cancers.
  • Regenerative medicine market is driven by surging trauma cases, genetic disorders, chronic diseases, and other infectious viruses.
  • The rising number of cancer patients worldwide is driving the growth of the regenerative medicine market.

Fujitsu conducts project with Takeda and National Cancer Center Japan to analyze and visualize of patient journey with ovarian cancer

Retrieved on: 
Friday, May 12, 2023
Insurance, Comment, Health, Takeda, ISPOR, Health Level 7, Takeda Pharmaceutical Company, Cancer, Research, Pharmacoeconomics, Organization, Platform, Patient, Physician, Data, Division, Informatics, National Cancer Center, Diagnosis, AI, HL7, Ovarian cancer, Environment, International Society, Pharmaceutical industry, Nursing, Medical imaging, Fujitsu

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.

Key Points: 
  • These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.
  • This study was conducted based on a joint research agreement that Fujitsu concluded with Takeda and the National Cancer Center Japan in May 2021 with the aim of identifying clinical challenges that will contribute to improving the quality and therapeutic efficacy of personalized ovarian cancer treatment.
  • In the future, the platform will be able to extract patient medical data and convert it into HL7 FHIR(2).
  • It includes electronic medical record data, medical accounting data, health checkup data, patient registry data, and data obtained from wearable devices.

BioLife Solutions Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
CGT, COVID-19, Media, GAAP, ID, EBITDA, Webcast, Growth, Takeda Pharmaceutical Company, Storage service provider, Media Operations Group, News, Total, Mobile phone, Bank, Video game, Beauty salon, Pharmaceutical industry, Q3, Q2, Q4, Sexton

BOTHELL, Wash., May 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2023.

Key Points: 
  • BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP).
  • Gross margin (GAAP) for the first quarter of 2023 was 35% compared with 28% for the first quarter of 2022.
  • Operating expense (GAAP) for the first quarter of 2023 was $51.3 million compared with $44.2 million for the first quarter of 2022.
  • Adjusted operating expense (non-GAAP) for the first quarter of 2023 was $25.5 million compared with $20.1 million for the first quarter 2022.

Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

Retrieved on: 
Friday, May 5, 2023
Takeda Pharmaceutical Company, Pressure, Injection, NASA RealWorld-InWorld Engineering Design Challenge, Risankizumab, EU, IV, TNF, Face, Takeda, JAK, SC, Mirikizumab, Eli Lilly and Company, Janssen, Ulcerative colitis, Traction, Patient, AbbVie, Physician, Need for Speed, CRL, BMS, Biosimilar, FDA, RealTime, Pharmaceutical industry, IL-23, Vedolizumab, Pfizer, Upadacitinib, Ustekinumab, UC

EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.

Key Points: 
  • EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab).
  • The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.
  • In the race to capture second-line UC patients, Janssen's Stelara (approved for UC in 2019) is currently favored by physicians.
  • Spherix will be monitoring the potential Entyvio SC US launch and the evolving UC market through its RealTime Dynamix™ advisory service.